162P: Molecular Markers in Advanced Non Small Cell Lung Cancer Patients Receiving Gemcitabine & Cisplatin

Journal of Thoracic Oncology - United States
doi 10.1016/s1556-0864(16)30272-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Triplet Chemotherapy Combination With Cisplatin, Gemcitabine and Docetaxel in Patients With Chemotherapy‑naive Advanced Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2013English

Advanced Non-Small Cell Lung Cancer in Elderly Patients

Breathe
PulmonaryRespiratory Medicine
2012English

Refractory Non-Small-Cell Lung Cancer Responding to Combination Chemotherapy With Gemcitabine and Cisplatin

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2003English

Fixed Dose Rate Versus Standard Dose Rate Infusion of Gemcitabine and Cisplatin in Advanced Stage Non-Small Cell Lung Cancer

Journal of Cancer Therapy
2015English

Clinical Significance of miRNA - 106a in Non-Small Cell Lung Cancer Patients Who Received Cisplatin Combined With Gemcitabine Chemotherapy

Cancer Biology and Medicine
Cancer ResearchOncology
2018English

Circadian Function in Patients With Advanced Non-Small-Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2005English

P1.01-13 a Study of S-1 Plus Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Gemcitabine Plus Vinorelbine in Elderly or Unfit Patients With Non-Small Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2000English

Health State Utility Values in Advanced Non-Small Cell Lung Cancer Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy